Literature DB >> 12811364

Transiently altered acetaminophen metabolism after liver transplantation.

Jeong M Park1, Yvonne S Lin, Justina C Calamia, Kenneth E Thummel, John T Slattery, Thomas F Kalhorn, Robert L Carithers, Adam E Levy, Christopher L Marsh, Mary F Hebert.   

Abstract

BACKGROUND AND OBJECTIVES: Acetaminophen (INN, paracetamol) is metabolized to N-acetyl-p-benzoquinone imine (NAPQI), a hepatotoxic metabolite, predominantly by cytochrome P450 (CYP) 2E1. Alterations in drug metabolism occur after organ transplantation. This study was designed to characterize acetaminophen disposition during the first 6 months after liver transplantation.
METHODS: Thirteen liver transplant patients received an oral dose of acetaminophen (500 mg) on days 2, 10, 90, and 180 after transplantation. Serial blood samples were collected for 8 hours, and urine was collected for 24 hours. Liver biopsy specimens were obtained from the donor liver during transplantation (day 0) and on days 10, 90, and 180 after transplantation.
RESULTS: There were significant time-dependent changes in acetaminophen metabolism after liver transplantation. When day 2 and day 10 were compared with day 180, the respective mean urinary recovery was 137% and 81% higher for thioether conjugates derived from NAPQI (P =.0002 and P =.01, respectively); 31% and 22% lower for acetaminophen sulfate (P =.0006 and P =.008, respectively); and 22% and 27% lower for acetaminophen glucuronide (P =.05 and P =.004, respectively). Metabolite formation clearances changed in concordance with the fractional urinary recovery. It was surprising that hepatic CYP2E1 content on day 10 after transplantation was only 20% higher, on average, than that found on day 180 (not significant). In contrast, hepatic CYP3A4 content was 984% higher, on average, when tissue from days 10 and 180 was compared after transplantation (P =.007).
CONCLUSIONS: Increased recovery of acetaminophen thioether conjugates during the first 10 days after liver transplantation was a result of impaired glucuronidation and sulfation and enhanced NAPQI formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811364     DOI: 10.1016/S0009-9236(03)00062-6

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

Review 1.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.

Authors:  Winnie Vogt
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

3.  Exposure to acetaminophen and all its metabolites upon 10, 15, and 20 mg/kg intravenous acetaminophen in very-preterm infants.

Authors:  Robert B Flint; Daniella W Roofthooft; Anne van Rongen; Richard A van Lingen; Johannes N van den Anker; Monique van Dijk; Karel Allegaert; Dick Tibboel; Catherijne A J Knibbe; Sinno H P Simons
Journal:  Pediatr Res       Date:  2017-06-21       Impact factor: 3.756

4.  Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen.

Authors:  Anne van Rongen; Pyry A J Välitalo; Mariska Y M Peeters; Djamila Boerma; Fokko W Huisman; Bert van Ramshorst; Eric P A van Dongen; Johannes N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.